Omeros | OMER - Current Assets


Omeros reported $69.65M in Current Assets for its fiscal quarter ending in June of 2025.





Current Assets Change Date
Adma Biologics USD 511.17M 44.66M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Cytokinetics USD 839.46M 77.51M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Immunic USD 188.76M 165.89M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
MacroGenics USD 182.52M 37.42M Mar/2026
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 514.96M 33.01M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Rockwell Medical USD 31.61M 1.42M Jun/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026
Xoma USD 110.71M 5.78M Sep/2025